Transition Therapeutics (Transition) has dosed the first patient in a Phase ll trial of its selective androgen receptor modulator (SARM) drug candidate TT701.

The study will assess the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue / low vitality, and physical dysfunction in men with prostate cancer who have undergone radical prostatectomy for organ-localised prostate cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase ll clinical trial is being conducted at Brigham and Women’s Hospital (BWH), US, led by principal investigator Dr Shalender Bhasin from BWH and will enrol up to 125 subjects at selected specialised clinical sites including BWH.

BWH research programme in men’s health: aging and metabolism director Shalender Bhasin said: "Sexual dysfunction, fatigue and other distressing symptoms of testosterone deficiency can greatly reduce the quality of life for men who have undergone radical prostatectomy for organ localised disease.

"The dosing of the first patient in this study is expected to generate a payment of $500,000 to Lilly."

"Therefore, the ability to treat these symptoms safely is an important unmet need."

The company stated that its wholly-owned subsidiary, Transition Therapeutics Ireland has exclusively licensed worldwide rights to the TT701 drug candidate from Eli Lilly and Company (Lilly).

The dosing of the first patient in this study is expected to generate a payment of $500,000 to Lilly.

Transition further noted that prostate cancer is the most common malignancy in American men, accounting for 29% of all diagnosed cancers and around 13% of all cancer deaths.

Its incidence is on the rise, partly due to increased screening with Prostate-specific antigen (PSA).

The majority of these men have low-grade, organ-confined prostate cancer and good prospects of long-term survival.